COMMUNIQUÉS West-GlobeNewswire

NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS

27/10/2017 - 17:45

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS COMPLETED PATIENT ENROLLMENT IN PHASE IIb CLINICAL STUDY OF IFNalpha KINOID FOR TREATMENT OF [...]

Shire plc : 3rd Quarter Results

27/10/2017 - 13:00

Shire reports strong earnings growth in Q3 2017; reiterates full year guidance Product sales increased 7%, mainly driven by rapid growth in Immunology franchise Generated $1.1 billion operating cash flow; remain on- [...]

Preferred Dental Technologies Inc. ("Company") (CSE: PDT): Addresses the growing digital dentistry market

27/10/2017 - 11:30

Prototypes for EAS have been successfully created in multiple materials WINNIPEG, Manitoba, Oct. 27, 2017 (GLOBE NEWSWIRE) -- PDT's Evolutionary Accessory Series (EAS) is used to create custom dental abutments for the [...]

Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review

27/10/2017 - 07:15

Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of oncology medicine filgrastim [...]

Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units

27/10/2017 - 07:00

The board of directors of Targovax ASA (the "Company") has on 27 October 2017, in accordance with the authorisations granted by the general meeting on 5 April 2017, resolved: - to increase the share capital of up to NOK [...]

Vistin Pharma ASA : Third quarter 2017 results - strong growth, capacity expansion on track

27/10/2017 - 07:00

Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) experienced strong growth in the third quarter of 2017, with a 20 per cent increase in revenue from its metformin business. With a strong financial [...]

ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD

27/10/2017 - 07:00

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform [...]

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

26/10/2017 - 22:01

Galapagos Q3 Results This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Composition of the Nomination Committee of Orion Corporation

26/10/2017 - 17:45

ORION CORPORATION STOCK EXCHANGE RELEASE 26 OCTOBER 2017 at 18.45 P.M. EEST Composition of the Nomination Committee of Orion Corporation The Board of Directors of Orion Corporation has elected the following persons to [...]

Origin(TM) Announces Positive Interim Results from Phase IIb Dose-Ranging Study for Diabetic Foot Ulcers

26/10/2017 - 14:30

Interim results demonstrate strong evidence of healing and favorable safety profile Highest-performing arm (4X per week, 12 minutes): · 95% mean wound-size reduction in 12 weeks · 71% of wounds achieved complete healing [...]

Inivata Announces World-Leading Scientific Advisory Board

26/10/2017 - 13:00

Inivata Announces World-Leading Scientific Advisory Board Research Triangle Park, NC and Cambridge, UK, 26 October2017 -- Inivata , a global clinical cancer genomics company utilizing an industry-leading liquid biopsy [...]

Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call

26/10/2017 - 13:00

SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' third quarter [...]

Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%

26/10/2017 - 13:00

DANVERS, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2018 revenue of $132.8 million, an [...]

Amer Sports to start repurchases of own shares

26/10/2017 - 13:00

Amer Sports Corporation STOCK EXCHANGE RELEASE October 26, 2017 at 2:00 p.m. Amer Sports to start repurchases of own shares Amer Sports Board of Directors has decided to utilize the authorization given by the Annual [...]

Saniona AB: Saniona decides to perform interim analysis of Tesomet study in patients with Prader-Willi syndrome

26/10/2017 - 12:45

PRESS RELEASE October 26, 2017 Saniona, a leading biotech company in the field of ion channels, today announces that nine out of a planned ten adult patients with Prader-Willi syndrome have completed or discontinued [...]

RECORDATI: VERY GOOD RESULTS IN THE FIRST NINE MONTHS 2017. CONTINUED GROWTH IN SALES +11.8%, OPERATING INCOME +21.8%, NET INCOME +20.6%. INTERIM DIVIDEND € 0.42 (+20%)

26/10/2017 - 12:01

Consolidated revenues € 963.8 million, +11.8%. EBITDA (1) € 342.0 million, +22.1% Operating income € 307.5 million, +21.8%. Net income € 219.8 million, +20.6%. Net financial position (2) : net debt of € 321.7 million. [...]

Amer Sports Corporation Interim Report January-September 2017

26/10/2017 - 12:00

Amer Sports Corporation INTERIM REPORT October 26, 2017 at 1:00 p.m. Amer Sports Corporation Interim Report January-September 2017 JULY-SEPTEMBER 2017 Net sales EUR 733.2 million (July-September 2016: 736.8). In local [...]

Orion Group Interim Report January-September 2017

26/10/2017 - 11:00

ORION CORPORATION INTERIM REPORT JANUARY-SEPTEMBER 2017 26 OCTOBER 2017 AT 12.00 NOON EEST Orion Group Interim Report January-September 2017 Orion's net sales in January-September 2017 totalled EUR 804 million (EUR 794 [...]

Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients

26/10/2017 - 08:00

Shire Receives European Approval for Label Extension of FIRAZYR ® (icatibant injection) for the Symptomatic Treatment of Acute Hereditary Angioedema (HAE) Attacks in Paediatric Patients FIRAZYR is the first and only [...]